As a result of an increasing emphasis on patient involvement in care and inclusion of QoL assessment in clinical trials, it is expected that the use of such patient-reported outcomes will see a further increase in clinical practice and pharmaceutical drug trials. Recent advances in item response theory and the use of computer technology, such as in the computerized adaptive testing would improve the measurement of patient-reported outcomes and in particular individually tailored QoL measurement. Rapidly evolving state of the art electronic tools, such as the interactive voice response and the high impact mobile touch-screen systems, supported by global infrastructure, would become more popular in drug trials because of their time and cost-efficiency, standardized administration, and improved data quality and accessibility.
Expert Rev Pharmacoeconomics Outcomes Res. 2009;9(3):271-283. © 2009 Expert Reviews Ltd.
Cite this: Burden of Skin Diseases - Medscape - Jun 01, 2009.